GNI files to take liver failure drug into Chinese trials
This article was originally published in Scrip
The GNI Group subsidiary Shanghai Genomics has applied to take its third pipeline project into clinical development in China, filing an IND with the Shanghai FDA to begin clinical trials with the hepatic failure therapy F573.
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.